NLS Pharmaceutics Announces Election of Additional Board Members
NLS Pharmaceutics Announces Election of Additional Board Members
- Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders
- Professor Florence Allouche Aknin, PharmD, MBA, is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraising
- 醫學博士克勞迪奧·巴塞蒂教授是伯爾尼大學醫院Inselspital神經病學系主任，也是伯爾尼大學醫學院院長，主要研究睡眠障礙
- 弗洛倫斯·阿盧什·阿克寧教授，藥學博士，工商管理碩士，是巴黎城市大學的教授，專門研究製藥創新、創業和籌款
ZURICH, SWITZERLAND / ACCESSWIRE / November 28, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that, subject to final approval of the extraordinary general meeting taking place on December 22, 2023, the Company's board of directors (the "Board") has elected Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join the Board effective January 1, 2024.
瑞士蘇黎世/ACCESSWIRE/2023年11月28日/NLS製藥有限公司（納斯達克股票代碼：NLSP，NLSPW）（“NLS” 或 “公司”）是一家專注於爲罕見和複雜中樞神經系統疾病患者發現和開發創新療法的瑞士臨床階段生物製藥公司，今天宣佈，視2023年12月22日舉行的特別股東大會的最終批准而定，，公司董事會（“董事會”）已選舉弗洛倫斯·阿盧什·阿克寧博士和克勞迪奧·巴塞蒂博士加入董事會，生效2024年1月1日。
"We are thrilled to have Florence and Claudio join our board of directors," said Alex Zwyer, Chief Executive Officer of NLS. "I am confident that Claudio's vast leadership in narcolepsy and sleep medicine and the fundraising and networking expertise of Florence will prove invaluable as we continue to evolve as a business and continue our mission to develop better therapies to safeguard and empower the brain throughout all stages of life."
NLS首席執行官Alex Zwyer說：“我們很高興弗洛倫斯和克勞迪奧加入董事會。”“我相信，克勞迪奧在發作性睡病和睡眠醫學領域的巨大領導地位以及佛羅倫薩的籌款和社交專業知識將被證明是無價的，因爲我們的業務將繼續發展，並繼續我們的使命，即開發更好的療法，在生命的各個階段保護和增強大腦的能力。”
Professor Claudio L. A. Bassetti, MD
克勞迪奧·巴塞蒂教授，醫學博士
Dr. Basetti received his Doctor of Medicine degree from the University of Basel and trained in Bern and Lausanne, with research fellowships in experimental neurophysiology and sleep medicine. In 2000, he was appointed professor of neurology at the University of Zurich and in 2009, founded the Neurocenter of Southern Switzerland. He is currently Chair of the Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern. He has served as president of the European Neurological Society, European Sleep Research Society, and European Academy of Neurology, among other prominent appointments. He has authored over 560 publications and speaks six languages. A global leader in sleep medicine, he has pioneered studies in sleep disorders and stroke, as well as made fundamental contributions to the etiology, pathophysiology and management of narcolepsy.
巴塞蒂博士在巴塞爾大學獲得醫學博士學位，並在伯爾尼和洛桑接受培訓，並獲得實驗神經生理學和睡眠醫學方面的研究獎學金。2000年，他被任命爲蘇黎世大學神經病學教授，並於2009年創立了瑞士南部神經中心。他目前是伯爾尼大學醫院Inselspital神經病學系主任和伯爾尼大學醫學院院長。他曾擔任歐洲神經學會、歐洲睡眠研究學會和歐洲神經病學會會長等重要職務。他撰寫了 560 多份出版物，會說六種語言。作爲睡眠醫學領域的全球領導者，他開創了睡眠障礙和中風的研究，併爲發作性睡病的病因、病理生理學和管理做出了根本性的貢獻。
Florence Allouche Aknin, PharmD, MBA
弗洛倫斯·阿盧什·阿克寧，藥劑學博士，工商管理碩士
A Doctor of Pharmacy and holding a Master's in Business Administration, Professor Allouche Aknin began her career as a biologist at AP-HP (Greater Paris Hospitals), managing the technology transfer office for 16 years and creating 75 start-ups. Dr. Allouche Aknin is an expert and mentor at the Paris incubators and has represented French technology internationally. She is a Professor of Pharmacy at the University Paris City and an elected member of the French National Academy of Pharmacy. She is also the President and Founder of Myrpharm Advisors, a start-up studio for the biopharmaceutical industry. In addition, in 2022, Dr. Allouch Aknin launched Sorbonne Venture, a €100M fund dedicated to health technology. She is also Chairwoman of the Board of Directors for PepKon, a French biotechnology company. Among her many awards, Dr. Allouche Aknin was elected "Woman of the Year 2017" by the French financial magazine La Tribune, Women's trajectory Award 2018 by HEC Paris, and Mercure Entrepreneurs Award 2019 by HEC Paris.
Allouche Aknin教授擁有藥學博士學位，擁有工商管理碩士學位，她的職業生涯始於AP-HP（大巴黎醫院）的生物學家，管理技術轉讓辦公室長達16年，創建了75家初創企業。Allouche Aknin博士是巴黎孵化器的專家和導師，曾在國際上代表法國技術。她是巴黎城市大學的藥學教授，也是法國國家藥學院的民選會員。她還是生物製藥行業的初創工作室Myrpharm Advisors的總裁兼創始人。此外，在2022年，阿盧奇·阿克寧博士創立了索邦風險投資公司，這是一家致力於健康技術的1億歐元基金。她還是法國生物技術公司PepKon的董事會主席。在她的衆多獎項中，阿盧什·阿克寧博士被法國金融雜誌評選爲 “2017年度女性” 《論壇報》，巴黎高等商學院頒發的2018年女性軌跡獎和巴黎高等商學院頒發的2019年美居企業家獎。
About NLS Pharmaceutics Ltd.
關於 NLS 製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq:NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmacetics Ltd.（納斯達克股票代碼：NLSP）是一家處於發展階段的全球生物製藥公司，與世界一流的合作伙伴和國際知名的科學家合作，專注於爲醫療需求未得到滿足的罕見和複雜中樞神經系統疾病患者發現和開發創新療法。NLS總部位於瑞士，成立於2015年，由經驗豐富的管理團隊領導，他們在開發和商業化候選產品方面有着良好的記錄。欲了解更多信息，請訪問。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
瑪麗安·蘭伯森（投資者和媒體）
NLS 製藥有限公司
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics Ltd.
來源：NLS 製藥有限公司
譯文內容由第三人軟體翻譯。